- Home
- KMDA vs NEWT Comparison
KMDA vs NEWT Comparison
Compare KMDA & NEWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- NEWT
- Stock Information
- Founded
- KMDA 1990
- NEWT 1998
- Country
- KMDA Israel
- NEWT United States
- Employees
- KMDA N/A
- NEWT N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- NEWT Major Banks
- Sector
- KMDA Health Care
- NEWT Finance
- Exchange
- KMDA Nasdaq
- NEWT Nasdaq
- Market Cap
- KMDA 310.1M
- NEWT 347.9M
- IPO Year
- KMDA N/A
- NEWT N/A
- Fundamental
- Price
- KMDA $5.97
- NEWT $13.80
- Analyst Decision
- KMDA Strong Buy
- NEWT Hold
- Analyst Count
- KMDA 2
- NEWT 3
- Target Price
- KMDA $14.50
- NEWT $12.33
- AVG Volume (30 Days)
- KMDA 40.9K
- NEWT 152.7K
- Earning Date
- KMDA 11-13-2024
- NEWT 11-06-2024
- Dividend Yield
- KMDA N/A
- NEWT 5.26%
- EPS Growth
- KMDA 230.67
- NEWT 27.09
- EPS
- KMDA 0.25
- NEWT 1.68
- Revenue
- KMDA $154,574,000.00
- NEWT $316,405,000.00
- Revenue This Year
- KMDA $14.85
- NEWT N/A
- Revenue Next Year
- KMDA $7.64
- NEWT $2.25
- P/E Ratio
- KMDA $22.94
- NEWT $8.59
- Revenue Growth
- KMDA 6.01
- NEWT 37.51
- 52 Week Low
- KMDA $4.58
- NEWT $10.07
- 52 Week High
- KMDA $6.53
- NEWT $15.25
- Technical
- Relative Strength Index (RSI)
- KMDA 77.16
- NEWT 57.37
- Support Level
- KMDA $5.84
- NEWT $12.83
- Resistance Level
- KMDA $6.06
- NEWT $14.73
- Average True Range (ATR)
- KMDA 0.12
- NEWT 0.45
- MACD
- KMDA 0.07
- NEWT 0.02
- Stochastic Oscillator
- KMDA 91.57
- NEWT 47.89
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions, It has developed a financial and technology-based business model that enables itself to acquire and process its clients in a very cost-effective manner. This capability is supported in large part by NewTracker, its patented prospect management technology software, that will allow NewtekOne clients to easily interact with NewtekOne subject matter experts in the areas of Banking, Lending, Payments, Technology, Payroll, and Insurance. It offers NewtekOne's clients a single online dashboard to access all of NewtekOne's business and financial solutions. It has four reportable segments Banking, Technology, NSBF, and Payments.